This event will feature presentations from:

• Rebecca Lang, Chair, AADC and CEO, QNADA – Why Harm Reduction is currently the most undervalued pillar of Australia’s National Drug Strategy
• Lucy Clynes, CEO, Hepatitis Australia – The new National Hepatitis Strategies – Priority Populations and Settings
• Ele Morrison, Deputy CEO, AIVL – How the harm reduction work of AIVL and its member organisations connects the priorities of the National Hepatitis and Drug Strategies
• John Ryan, CEO, Penington Institute – Overview of Penington’s Annual Overdose snapshot and policy implications
• Paul Dessauer, CEO, Peer Based Harm Reduction WA – Peer Based Harm Reduction WA: Case study of the scope of harm reduction work undertaken by peer-based drug user organisations.

Plus a panel session and audience Q&A responding to the presentations and elaborating on the event topic.

Register here.